Strategic collaboration with OnDosis

We are proud to announce a super exciting collaboration with OnDosis – an AstraZeneca spin-off medtech company. Their products can intuitively and intelligently deliver the perfect medication dose. The intention is to combine the companies’ groundbreaking technologies to enable the development of unique products for the treatment of Parkinson’s disease, see press release below.

Joint press release

OnDosis and Stardots enter into a strategic collaboration to combine cutting-edge technologies and enable better therapies for Parkinson’s disease
OnDosis, a Swedish medical technology company that develops a unique device platform for flexible and individualized dosing of drugs, and Stardots, a Swedish digital health company that develops products in neurology, today announce that the companies have entered into a strategic collaboration. The intention is to combine the companies’ groundbreaking technologies to enable the development of unique products for the treatment of Parkinson’s disease.

OnDosis, a medical technology company spun off from AstraZeneca, is revolutionizing the way patients take their medication. OnDosis is developing a new way to dose drugs through an intuitive handheld device that integrates drugs with intelligent dosing, sensors and digital therapies. With its technology platform, OnDosis is strategically positioned in the convergence of precision medicine and digital health.
Stardots is derived from research from Uppsala University and Uppsala University Hospital. The company is developing a global, modular, and scalable digital health platform that gives patients, caregivers and relatives access to digital markers that facilitate the understanding and treatment of Parkinson’s disease, as well as offering an opportunity for more individualized care.

The purpose of the collaboration is to jointly enable the development of innovative treatments based on the companies’ respective core competencies in microdosing and symptom quantification of Parkinson’s disease. By combining the companies’ unique technology and knowledge, a new chapter in precision medicine is made possible, where dosing, measurement of results and feedback enable better and more individualized care. The goal is significantly better quality of life for patients and reduced costs for society.

Neurological disorders are the leading cause of disability globally, the fastest growing of which is Parkinson’s disease, a progressive incurable disease that is essentially a movement disorder that affects muscle control and balance. Today, the care of Parkinson’s patients is subjective, unequal and costly and the treatment differs greatly from region to region or from country to country. The collaboration between OnDosis and Stardots is expected to eventually lead to a significantly improved quality of life for the more than 10 million people around the world who suffer from the disease.
– “We are very happy about the fantastic opportunity opened up by the collaboration with Stardots. OnDosis and Stardot’s technologies combined are based on a very strong logic, where our companies’ joint expertise and the commitment of our teams will enable an acceleration towards our goal of revolutionizing the way patients take their medicine.“, says Martin Olovsson, CEO of OnDosis
– “When we first met the team from OnDosis, we immediately felt the enormous potential that a partnership between the companies can bring. Together, we are convinced that we will be able to offer unique medical devices for better and more individualized care, with increased quality of life for the patient and reduced costs for society“, says Daniel Petrini, CEO of Stardots.

For more information, please contact:
Martin Olovsson, CEO of OnDosis, +46 (0)76 772 85 01, m.olovsson@ondosis.com
Daniel Petrini, CEO of Stardots, +46 (0)70-782 70 01, daniel.petrini@stardots.se

About OnDosis
A Swedish life science company that intends to revolutionize the way patients take their medicines. The idea is to deliver the perfect dose – individualized, intuitive and intelligent – in a form that is easier to consume. OnDosis has developed a proprietary technology platform based on a connected handheld device that delivers personalized and easily adjusted doses of oral medications and enables integration with digital technologies. By combining traditional drug-based treatments and
digital therapies, OnDosis strives to fulfill its purpose: to ensure that patients receive exactly the medicine they need to live the life they deserve. Read more on www.ondosis.com

About Stardots
Stardots AB develops and markets products in digital health and for neurology, with an initial focus on Parkinson’s disease. The company’s IP is based on mathematical models of symptoms and treatment optimization, originally from research at Uppsala University developed in close collaboration with the Department of Neurology and clinical trials at Uppsala University Hospital. Stardots is building a global, modular and scalable digital health platform that gives patients, caregivers and relatives access to digital markers that facilitate the understanding and treatment of the disease, and offers an opportunity for optimization of more advanced Parkinson’s care e.g. deep brain stimulation (DBS), pump treatment and individualized precision medicine solutions, such as microtablets. Read more at www.stardots.se